- Hong Kong
- /
- Healthcare Services
- /
- SEHK:2325
Yunkang Group Full Year 2024 Earnings: CN¥1.33 loss per share (vs CN¥0.17 loss in FY 2023)
Yunkang Group (HKG:2325) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥711.9m (down 20% from FY 2023).
- Net loss: CN¥791.7m (loss widened by CN¥689.4m from FY 2023).
- CN¥1.33 loss per share (further deteriorated from CN¥0.17 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Yunkang Group Earnings Insights
Looking ahead, revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's shares are down 28% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Yunkang Group that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2325
Yunkang Group
Operates as a medical operation service provider in the People's Republic of China.
Reasonable growth potential with adequate balance sheet.
Market Insights
Community Narratives
